Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

Steven Black, Juhani Eskola, Claire Anne Siegrist, Neal Halsey, Noni MacDonald, Barbara Law, Elizbeth Miller, Nicholas Andrews, Julia Stowe, Daniel Salmon, Kirsten Vannice, Hector S. Izurieta, Aysha Akhtar, Mike Gold, Gabriel Oselka, Patrick Zuber, Dina Pfeifer, Claudia Vellozzi

Research output: Contribution to journalArticlepeer-review

174 Citations (Scopus)

Abstract

Because of the advent of a new influenza A H1N1 strain, many countries have begun mass immunisation programmes. Awareness of the background rates of possible adverse events will be a crucial part of assessment of possible vaccine safety concerns and will help to separate legitimate safety concerns from events that are temporally associated with but not caused by vaccination. We identified background rates of selected medical events for several countries. Rates of disease events varied by age, sex, method of ascertainment, and geography. Highly visible health conditions, such as Guillain-Barré syndrome, spontaneous abortion, or even death, will occur in coincident temporal association with novel influenza vaccination. On the basis of the reviewed data, if a cohort of 10 million individuals was vaccinated in the UK, 21·5 cases of Guillain-Barré syndrome and 5·75 cases of sudden death would be expected to occur within 6 weeks of vaccination as coincident background cases. In female vaccinees in the USA, 86·3 cases of optic neuritis per 10 million population would be expected within 6 weeks of vaccination. 397 per 1 million vaccinated pregnant women would be predicted to have a spontaneous abortion within 1 day of vaccination.

Original languageEnglish
Pages (from-to)2115-2122
Number of pages8
JournalThe Lancet
Volume374
Issue number9707
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines'. Together they form a unique fingerprint.

Cite this